Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 69

Results For "stent"

930 News Found

IIT Kanpur and Apollo Hospitals join hands for research collaboration
News | January 04, 2023

IIT Kanpur and Apollo Hospitals join hands for research collaboration

The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology


USFDA accepts for review the biologics license application for Pfizer’s Investigational MenABCWY in adolescents
Drug Approval | December 31, 2022

USFDA accepts for review the biologics license application for Pfizer’s Investigational MenABCWY in adolescents

If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine


Lupin receives USFDA approval for Brivaracetam Tablets
Drug Approval | December 23, 2022

Lupin receives USFDA approval for Brivaracetam Tablets


Stake sale in GMM Pfaudler by Pfaudler
News | December 19, 2022

Stake sale in GMM Pfaudler by Pfaudler

Post the sale, Patel family has become the single largest promoter shareholder in the company


Surendran Chemmenkotil to join as CEO of Metropolis Healthcare
People | December 12, 2022

Surendran Chemmenkotil to join as CEO of Metropolis Healthcare

He is a seasoned leader with 34 years of rich and diverse experience across geographies and consumer facing companies such as Xerox India and Bharti Airtel


Lupin launches generic version of Pennsaid in the US
News | December 12, 2022

Lupin launches generic version of Pennsaid in the US

Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)


Govt. to create a vibrant ecosystem where women can flourish and harness full potential: Dr. Bharati
Policy | December 08, 2022

Govt. to create a vibrant ecosystem where women can flourish and harness full potential: Dr. Bharati

More women centric initiatives being the need of the hour for holistic development


Jemperli RUBY phase III trial met its primary endpoint
Clinical Trials | December 05, 2022

Jemperli RUBY phase III trial met its primary endpoint

Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival